R Squared’s PMV Pharmaceuticals PMVP Stock Holding History

R Squared’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,300	Closed	-$20.1K	–	1181
2024 Q4	$20.1K	Buy	+13,300	New	+$21.1K	0.02%	873

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

R Squared's PMVP Position: Q1 2025 in Review

R Squared sold out of PMV Pharmaceuticals (PMVP) in Q1 2025, closing a stake of 13,300 shares — an estimated $20.1K sold.

R Squared first reported a position in PMVP in Q4 2024 and held it in 1 quarter. The position peaked at $20.1K in Q4 2024. 55 funds tracked by Wall St. Rank hold PMVP as of Q1 2025.

R Squared reported no remaining PMV Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 13,300 PMV Pharmaceuticals shares in Q1 2025, an estimated $20.1K.
R Squared first reported a position in PMV Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's PMV Pharmaceuticals position peaked at $20.1K in Q4 2024.
55 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.